Severe mitral regurgitation is common and results in a poor prognosis in patients with either symptoms or severe ventricular dilatation. While mitral regurgitation has traditionally necessitated surgical repair or replacement, new transcatheter methods, such as the IntrepidTM transcatheter mitral valve replacement, has recently emerged. The Intrepid system is a circular, self-expanding, tri-leaflet bovine pericardial prosthesis housed within a nitinol frame. In early feasibility studies, the Intrepid prosthesis has been found to be effective for relief of mitral regurgitation and associated with functional improvement in the majority of survivors.
Introduction
Severe mitral regurgitation (MR) is common and results in chronic volume overload, with a poor prognosis in patients with either symptoms or severe ventricular dilatation (1) (2) (3) . Traditionally, MR necessitated surgical repair or replacement, however, new transcatheter methods have recently emerged. These methods offer a relatively less invasive alternative to open surgery and may help address an unmet clinical need for MR. In this report, we describe the methodology and present outcomes with the Medtronic Intrepid TM system for transcatheter mitral valve replacement (TMVR) (4).
The Intrepid TM TMVR system
The Intrepid TM TMVR system is a self-expanding, trileaflet bovine pericardial prosthesis housed within a nitinol frame. The frame consists of two parts: a circular outer fixation frame that comes in three sizes (43, 46, or 50 mm diameter) and a 27-mm circular inner stent frame (27 mm) ( Figure 1 ). Implantation and fixation for anchoring is selfcentering and symmetrical. The outer frame engages the dynamic native mitral valve anatomy with a flexible atrial brim that facilitates visualization under ultrasound during implantation. Fixation of the Intrepid TM prosthesis is achieved through oversizing and design features of the outer frame that allow the prosthesis to wedge itself in the subannular mitral space. The atrial portion of the outer frame is relatively flexible and conforms to the native annulus, while the ventricular portion is relatively stiffer. Small cleats on the outer frame also act as frictional elements to engage the native mitral leaflets. The dual frame structure allows the inner frame to remain circular throughout the cardiac cycle, without intrusion from the shape and motion of the outer frame and native annulus. There is no need for rotational orientation during device implantation. Risk of left ventricular outflow tract (LVOT) obstruction is minimized with a device profile of 17 to 18 mm. A hydraulically actuated delivery catheter is used to deliver the Intrepid TM with a 35 French (Fr) access sheath through the apex of the left ventricle, although, a transfemoral, transseptal version of the prosthesis is currently under development.
Implantation procedure
Patients with symptomatic primary or secondary MR may be considered for TMVR with the Intrepid TM system. All patients undergo contrast-enhanced, cardiac computed tomography (CT) of the mitral valve annulus to determine suitability and choice of the prosthesis size (6, 7) . In general, a prosthesis size is chosen that will allow 10% to 30% oversizing in the mitral annular perimeter, inter-commissural diameter and septal-lateral diameter, while minimizing risk of LVOT obstruction. While there are no set boundaries for neo-LVOT area, a predicted value of >1.3 cm 2 is typically used. The cardiac CT scan is used to determine the access site for the thoracotomy and the location for placement of the sheath in the left ventricle. Patients are placed under general anesthesia for the procedure, with guidance by transesophageal echocardiography (TEE) and fluoroscopy ( Figure 2 
Patient outcomes
In 2015, a global feasibility study of the Medtronic Intrepid TM system was initiated with recruitment from 14 hospitals in Australia, Europe, and the United States (5). For this study, patients with symptomatic, severe MR who were at high or prohibitive surgical risk were considered for enrolment, with primary exclusion criteria being an ejection fraction <20%, mitral valve calcification, hemodynamic instability, severe pulmonary hypertension, severe renal insufficiency and prior mitral valve surgery or intervention. The results of the initial 50 patients (mean age, 72.6±9.4 years; 58% men; Table 1 ) who were consecutively enrolled through July 2017 have been published. Severe heart failure was common, with NYHA III or IV symptoms present in 86%. The predominant mechanism of MR was secondary (84% of patients Table 2) . At a median follow-up of 173 (IQR, 54, 342) days, there were four additional deaths after 30 days (between day 54 and 122) but no deaths after 4 months ( Figures 3,4) ; three of these late deaths were due to sudden cardiac arrest and one due to intracranial haemorrhage in the setting of an unwitnessed fall. Overall, the one-year survival rate was 77%. Mild para-prosthetic MR was present in three patients (7.1%), while mild prosthetic MR occurred in eight patients (19.0%) ( Figure 5 ). For the survivors, mild or no symptoms of heart failure (i.e., NYHA functional class I or II) were present in 79% (P<0.0001 vs. baseline), and, for a subset of patients, there were significant improvements in the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores (56.2±26.8 vs. 31.7±22.1; P=0.011) and six-minute walk distance ( Figure 6 ). Pulmonary artery systolic pressure on transthoracic echocardiography decreased from 46.7±14.7 to 37.2±9.7 mmHg at followup (P<0.0001). No valve degeneration occurred and there were no instances of hemolysis, device embolization or thrombosis. Data are presented as n (%) or mean ± SD. *, patients with GFR <30 mL/min/m 2 were excluded; **, patients with PASP >70 mmHg were excluded; # , albumin was not measured in 11 patients; † , anemia was defined as haemoglobin <13.0 g/dL in men or <12.0 g/dL in women; † † , defined as alanine transferase >40 U/L and was measured in 42 patients. GFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; PPM, permanent pacemaker; STS, Society of Thoracic Surgeons. Re-hospitalization for heart failure 4 (8.0) 8 (19.5)
Data are presented as n (%). *, reoperation for wound infection at incision site; † , the endocarditis event was related to placement of a pacemaker lead.
The APOLLO clinical trial
A multicenter, pivotal clinical trial was initiated in the fall of 2017 to examine the effectiveness and safety of the Intrepid TM System in patients with severe, symptomatic MR. The trial consists of two arms, with one-arm randomizing TMVR with vs. traditional surgery (n=650), and a second arm that will treat patients who are ineligible for surgery as a single cohort (n=550). For patients in the randomized cohort, the predicted risk of operative mortality is ≥3% with a combined <35% risk of mortality or irreversible major morbidity at 30 days, and patients must have an estimated life expectancy of >24 months. For the single-arm cohort, the predicted risk of operative mortality 
Conclusions
Feasibility studies have demonstrated excellent results with the Intrepid system, with over 95% of patients successfully treated, a minimal learning curve, no device malfunction and improvements in symptom status and quality-of-life among the survivors. For all patients, meticulous attention to apical access techniques and post-operative heart failure care is essential. Ongoing clinical trials will determine the potential role of the Intrepid system compared with surgery and other transcatheter technologies in patients with MR.
Acknowledgements
None.
Footnote

Conflicts of Interest:
The authors have no conflicts of interest to declare. 
